3,4-Dimethoxybenzoic Acid

93-07-2

Chenglian Pharmaceutical is an innovative high-tech pharmaceuticεal enterprise that is market-oriented and realizes industrial development through R&D innovatiεon and technology transformation.

key word:

technology Pharmaceutical

Category:

Consulting
Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large h&ealth industry finance platform company integrating Ωpharmaceutical, intelligent medical, bio pharmaceutical R&D, industrial pΩroduction and sales.

The chemical reactions involved in the existing products include Foucau☆lt reaction, nitration reaction, sulfonation reaction, hydr©ogenation reaction, fluorination reaction, chlorination reaction, bromination reactio≠n, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) in₩hibitor developed by Merck. In October 2006, Sitagliptin phosphate Januvia was ™approved by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mel♠litus. The characteristics of this drug are that it can stimulate insulin secretion while reducing ≠hunger without causing weight gain. Hypoglycemia and ede™ma will not occur, and it is suitable for diabetic patients with poor blood ₩glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterpri®se that is market-oriented and realizes industrial development through R&D innov®ation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is ≤one of the most important products for the treatment of arthritis. It is well tolerated and ✔has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antago×nists. In clinical application, it has good therapeutic effect on atopic asthma and other types o‌f bronchial asthma, and the market prospect is huge. In the major category of asthma drugs, leukotεriene receptor antagonists have the fastest growing↔ market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orien≈ted and realizes industrial development through R&∑D innovation and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the seco<nd drug approved by FDA for Alzheimer's disease in the United States. Its treatment reaches the ÷target dose and has low toxic and side effects. It has been widely recognized by our medical coπmmunity, and good tolerance is its biggest advantage. In Oct₹ober 1999, Donepezil was launched in China under the trade name "Aricept", which is the main§ chemical drug against Alzheimer's disease. At present, CFDA has approved a numb&er of domestic enterprises to produce donepezil preparations, th'e main dosage forms are tablets, capsules, dispersive tablets, oσral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban  (Eliquis, Bristol-Myers Squibb/Pfizer), a direct oral factor Xa inhibitβor, was approved for use in the 27 EU member states. The world's first→ drug approved to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or• knee replacement. From June 2019 to June 2020, the annu®al sales of apixaban products overseas reached about $§15.4 billion, with a year-on-year growth of nearly 32%, and the API cons↕umption reached about 23,960 kg, with a year-on-year growthσ of about 28%. Compared with its main competitor, Rivaroxaban, the drug's annual overseas sales a₹re about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceut∑ical enterprise that is market-oriented and realizes industrial developmeφnt through R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufacture d by Genzyme. On December 29, 2004, it was approved ¶by FDA for the treatment of refractory or relapsed acute lymphoblasticπ leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceu®tical enterprise that is market-oriented and realizes industrial development th rough R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services, E-ma<il: 2880705932@qq.com